ResMed Beats Q3 Estimates with 7.17% Revenue Growth

Key Facts

1ResMed reported an actual EPS of $37.29, beating the consensus estimate of $33.74.

2Company revenue reached $20.96 billion, surpassing the expected $20.56 billion with a 7.17% year-over-year growth.

Amid a robust performance in the healthcare sector, ResMed Inc reported strong financial results for Q3 2024, delivering a double beat on both top and bottom lines. According to reports, the company achieved an actual EPS of $37.29, significantly surpassing the consensus estimate of $33.74. This performance underscores the company's ability to outperform market expectations within a competitive operating environment.

On the revenue front, the company reached $20.96 billion, exceeding the anticipated $20.56 billion and representing a 7.17% year-over-year growth. This increase was driven by demand exceeding market consensus, strengthening the bullish outlook for RMD within the medical technology space. These results were further supported by operational efficiencies that led to an earnings beat of approximately 10.5% over estimates.

Regarding stock performance, RMD closed at $192.91 (as of July 22, 2026), having reached a day high of $197.08. Traders are currently monitoring support levels near the recent low of $191.67. While the upcoming economic calendar shows no immediate corporate catalysts, market participants will continue to digest these earnings results in the context of broader sector trends.